+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anterior Uveitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 112 Pages
  • June 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4896047
The anterior uveitis treatment market will show rapid growth due to the increasing cases of the uveitis and the development of novel drugs and treatments and it is expected to grow with a CAGR of 5.8% over the forecasted period.

The COVID-19 pandemic has disrupted care patterns as missed visits have led to the potential for significant disease progression in some patients with noninfectious uveitis. Uveitis patients may be at higher risk than the general population of contracting COVID-19 or suffering a more severe course of the virus. The article "How COVID-19 has altered uveitis management" published in March 2021, there was an 86-percent reduction in outpatient treatment for uveitis in spring 2020 compared to the same period in 2019, thereby affecting the market significantly. However, with the increase in vaccination programs, the outpatient departments started operating at full capabilities and are expected to grow during the study period.

There has been an increasing prevalence of uveitis across the globe leading to blindness. For instance, as per the study "Incidence, prevalence, and risk factors of infectious uveitis and scleritis in the United States: A claims-based analysis" published in August 2020, the mean prevalences of infectious anterior, intermediate, posterior, panuveitis, and scleritis were 27.7, 0.17, 23.4, 4.4, and 4.6, per 100,000, respectively. Overall risk of prevalent infectious uveitis increased with age, female sex, non-Hispanic white race, as well as the East South Central census division. Uveitis is a sight-threatening inflammatory disease affecting the uveal layer of the eye. Redness of eyes, blurring of the vision, the small size of the pupil, and sensitivity to light can be possible symptoms of anterior uveitis, which, if not treated, can result in permanent blindness. Thus, there are new developments in the applications of products and treatment modalities that are ongoing.

New treatment options for uveitis such as corticosteroids and anti-inflammatory drugs are already gaining traction in the market. The growing product launches and rising research and development studies will boost the market growth. For instance, in May 2021 Oculis S.A. reported positive data from two clinical proof of concept Phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in Dry Eye Disease (DED) and Acute Anterior Uveitis (AAU). Such positive results from the studies will ease ist approval process, thereby boosting the market.

Furthermore, in August 2021, Cipla received final approval for its abbreviated new drug application for difluprednate ophthalmic emulsion 0.05% from United States Food and Drug Administration. Difluprednate ophthalmic emulsion 0.05% is the generic version of Novartis’s Durezol and is used for the treatment of inflammation and pain associated with ocular surgery as well as for the treatment of endogenous anterior uveitis. Thus, increasing product approvals addresses the rising demand for anterior uveitis therapeutics, thereby boosting the market.

In addition, other factors such as the growing geriatric population, rising incidence of the disease, and new product developments are also expected to be some of the driving factors in the growth of the market. However, high cost associated with medications and side effects associated with corticosteroids treatment is expected to hinder the market growth.

Key Market Trends

Corticosteroids Segment is Expected to Dominate the Treatment Type Segment During the Forecast Period

Corticosteroids are found to dominate the uveitis treatment market as they are first-line therapies for uveitis management and are given systemically or locally, in the form of drops, periocular injection, intravitreal suspension, or intravitreal implant. They are the most preferred option over biologics however researchers are currently exploring biological therapies for the treatment of uveitis. The main advantage of corticosteroids is their ability to quickly and effectively control inflammation early on in the course of uveitis.

Corticosteroids are also used in sustained release treatment, i.e., in ocular implants. It has thus shown significant results to cure the condition and researchers are also exploring biological therapies to treat anterior uveitis. In addition, corticosteroids and anti-inflammatory drugs are found gaining traction in the market.

Moreover, rising research and development studies highlighting the fficcaiesof treating corticosteroids in non infectious uveitis will increase its adoption, thus driving the segment. For instance, the study "Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study" published in January 2022 stated that corticosteroids are the standard of care treatment for noninfectious uveitis and can be administered topically, regionally, or systemically. They are commonly used in the treatment of noninfectious uveitis, including in cases of active intraocular inflammation and uveitic macular edema.

Thus, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period.

North America is Anticipated to Dominate the Anterior Uveitis Treatment Market

North America is found dominating the market owing to the rising prevalence of the uveitis disease in the United States. There is also an increasing number of key players in the region that is leading to the high growth of this regional segment. The other factors resulting in the growth of the market is the growing geriatric population, rising prevalence of uveitis in the region, and increasing investments in research and development by drug manufacturing companies for innovating new treatments such as corticosteroids.

The growing burden of uveitis in the region will boost the demand for its therapeutics, thus driving the market. According to an article published by the Ocular Immunology and Uveitis Foundation in April 2022, uveitis has an estimated prevalence of about 38 cases per 100,000 population, and an incidence of 15 cases per 100,000 population. It is estimated that uveitis afflicts 109,000 people in the United States and that 43,000 new cases a year are diagnosed. Thus, the high prevalence of uveitis will drive the therapeutics for anterior uveitis as anterior uveitis is the most common of uveitis.

Additionally, the product approvals and launches, rise in investments, and adoption of key strategies such as partnerships, mergers, acquisitions, and others are expected to drive the market growth. Moreover, rising research and development studies proving the efficacies of anterior uveitis treatment will drive the market growth. For instance, in September 2021, Tarsier Pharma inititated Phase 3 trial TRS4VISION by randomizing the first patient for treatment. TRS4VISION is a Phase 3 randomized, active-controlled, double-masked study to evaluate the safety and efficacy of TRS01 eye drops in the treatment of subjects with active non-infectious anterior uveitis including subjects with uveitic glaucoma. positive results from such studies will ease the approval process of TRS01 and increase its adoption, thus boosting the market.

Thus, above-mentioned factors is expected to drive the market growth in the United States during the study period.

Competitive Landscape

The studied market is consolidated and moderately competitive. There has been a presence of a considerable number of companies that are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. Various companies are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events. Major players in the market include Novartis AG, AbbVie Inc., Aciont Inc., Tarsier Pharma Ltd, and Amgen among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of the Uveitis
4.2.2 Development of Novel Drugs and Treatments
4.3 Market Restraints
4.3.1 High Cost Associated with the Medications
4.3.2 Side Effect Associated with Corticosteroid Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - in USD Million)
5.1 By Treatment Type
5.1.1 Corticosteroids
5.1.2 Cycloplegic Agents
5.1.3 Anti-TNF Agents
5.1.4 Immunosuppressants
5.2 By Distribution Channel
5.2.1 Hospitals Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Aldeyra Therapeutics, Inc.
6.1.3 Amgen
6.1.4 Clearside Biomedical, Inc.
6.1.5 Novartis AG
6.1.6 Aciont Inc.
6.1.7 Bausch & Lomb Incorporated
6.1.8 Sirion Therapeutics, Inc.
6.1.9 Santen Inc.
6.1.10 Tarsier Pharma Ltd
6.1.11 Oculis

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Aldeyra Therapeutics, Inc.
  • Amgen
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Aciont Inc.
  • Bausch & Lomb Incorporated
  • Sirion Therapeutics, Inc.
  • Santen Inc.
  • Tarsier Pharma Ltd
  • Oculis